Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

IGF2BP1 (insulin-like growth factor 2 mRNA binding protein 1)

Written2010-11Theoni Trangas, Panayotis Ioannidis
Department of Biological Applications, Technologies University of Ioannina, Ioannina, Greece (TT); National Reference Center for Mycobacteria, Sotiria Hospital, Athens, Greece (PI)

(Note : for Links provided by Atlas : click)


HGNC Alias symbIMP-1
HGNC Alias nameIGF II mRNA binding protein 1
HGNC Previous nameinsulin-like growth factor 2 mRNA binding protein 1
LocusID (NCBI) 10642
Atlas_Id 40969
Location 17q21.32  [Link to chromosome band 17q21]
Location_base_pair Starts at 48997385 and ends at 49056145 bp from pter ( according to GRCh38/hg38-Dec_2013)  [Mapping IGF2BP1.png]
Local_order The IGF2BP1 gene is located on the plus strand on chromosome 17, at 17q21.32. This gene starts at 47074774 and ends at 47133507 bp from pter, encompasses 58734 bp and lies 5' of the gene B4GALNT2, encoding beta-1,4-N-acetyl-galactosaminyl transferase 2.
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)
IGF2BP1 (17q21.32)::IGF2BP1 (17q21.32)KAT7 (17q21.33)::IGF2BP1 (17q21.32)NCL (2q37.1)::IGF2BP1 (17q21.32)
NSD2 (4p16.3)::IGF2BP1 (17q21.32)PRKCA (17q24.2)::IGF2BP1 (17q21.32)RAI1 (17p11.2)::IGF2BP1 (17q21.32)
ZBTB8OS (1p35.1)::IGF2BP1 (17q21.32)
Note The IGF2BP1 gene encodes a member of the IGF-II mRNA-binding protein (IMP) family (RRM IMP/VICKZ family).


Description There are 4 probable alternative promoters driving transcription of IGF2BP1 and two of them have been experimentally confirmed (Gu et al., 2008). The upstream (promoter) region contains binding sites for the following transcription factors: delta CREB, CREB, NF-kappaB1, NF-kappaB, AP-1, HNF4 alpha2, FOXO1a, MZF-1, Max and c-Myc. Beta-catenin/TCF4 binding and activation of transcription has been experimentally confirmed (Gu et al., 2008).
Transcription Two protein coding transcripts exist resulting from alternative splicing:
Transcript variant 1 (NM_006546). The length of this transcript is 8769 nt and encompasses all 15 exons (exon 1: 509 bp, exon 2: 60 bp, exon 3: 48 bp, exon 4: 51 bp, exon 5: 63 bp, exon 6: 281 bp, exon 7: 134 bp, exon 8: 122 bp, exon 9: 135 bp, exon 10: 122 bp, exon 11: 119 bp, exon 12: 74 bp, exon 13: 131 bp, exon14: 113 bp, exon 15: 6973 bp).
Several alternative 3' ends (polyadenylation sites) exist at exon 15 3'-UTR (marked by flags in the figure above). Translation starts at +335 and ends at +2068.
Transcript variant 2 (NM_001160423.1). It encompasses 8352 bp and lacks two consecutive in-frame exons (6 and 7).
Other spliced variants have been reported without corresponding protein product recorded.


  IGF2BP1 protein translated from transcript 1 variant.
Description The IGF2BP1 protein translated from the transcript variant 1 consists of 577 aa (63,48 kD) and has 2 highly conserved RRM motifs belonging to the RNA recognition motif (RRM) superfamily and 4 KH domains (NP_006537.3). The third and fourth KH domains constitute both the protein dimerization motif and the RNA binding domain. The four KH domains promote granule formation and stress granule targeting (Stöhr et al., 2006). Two nuclear export signals (NES) exist within the second and fourth KH domains (Nielsen et al., 2003). The KH domains have been implicated in the suppression of HIV-1 infectivity (Zhou et al., 2008). Phosphorylation sites are marked (Bennetzen et al., 2010; Dephoure et al., 2008). Phosphorylation of Tyrosine 396 prevents RNA binding and translation inhibition of beta-actin mRNA (Hüttelmaier et al., 2005).
The IGF2BP1 protein translated from transcript 2 variant is predicted to consist of 438 aa (48.597 kD) and contain 2 RRM and 3 KH domains (NP_001153895.1).
  IGF2BP1 protein translated from transcript 2 variant.
Expression IGF2BP1 is widely expressed in fetal tissues (liver, lung, kidney, thymus, etc), placenta and CD34+ cord blood cells (Nielsen et al., 1999; Ioannidis et al., 2001; Ioannidis et al., 2005). Postnatally it is expressed in ovary (oocytes and granulosa cells), in testis (spermatogonia), in semen (Hammer et al., 2005) and in intestinal crypts (Nielsen et al., 1999; Dimitriadis et al., 2007). It is expressed de novo in kidney, prostate, trachea, testis, ovarian and lung cancer, melanoma, mesenchymal and brain tumors. At protein level, it is expressed in testicular, lung and colon cancer.
Localisation IGF2BP1 has been detected in the nucleus, cytoplasm, cytoplasmic mRNPs, granules (Nielsen et al., 2002; Nielsen et al., 2003). In stress granules IGF2BP1 co localizes with G3BP1 and TIAL1 (Stöhr et al., 2006). It has also been detected in lamellipodia (Yaniv et al., 2003), growth cones and the leading edge of developing axons (Eom et al., 2003).
Function mRNA translation: IGF2BP1 regulates translation by binding the 5'-UTR of the mRNA of certain genes, including insulin-like growth factor 2 (Nielsen et al., 1999), and beta actin (Hüttelmaier et al., 2005). It has been identified in a HCV IRES-mediated translation complex along with EIF3C and RPS3, enhancing translation of the Hepatitis C virus (HCV) RNA-replicon via the internal ribosome entry site (IRES), without affecting 5'cap-dependent translation (Weinlich et al., 2009). IGF2BP1 binds the adenine-rich autoregulatory sequence (ARS) of the 5'-UTR of the PABPC1 mRNA in collaboration with CSDE1 and PABPC1 proteins and causes translational repression (Patel and Bag, 2006; Patel et al., 2005).

mRNA stabilization: IGF2BP1 binds to the coding region mRNA stability determinant (CRD) of c-myc mRNA and protects it from endonucleolytic cleavage (Doyle et al.,1998; Lemm and Ross, 2002). It protects MDR-1 mRNAs from endonucleolytic cleavage by binding to a coding region element (Sparanese and Lee, 2007). Also binds to the coding region of betaTrCP1 mRNA and stabilizes it by disrupting miRNA-dependent interaction with AGO2 (Noubissi et al., 2006; Elcheva et al., 2009). Binds and stabilizes GLI1 mRNA causing an elevation of GLI1 expression and transcriptional activity (Noubissi et al., 2009). IGF2BP1 binds to multiple elements in the 3'-UTR of the CD44 mRNAs and stabilizes this mRNA (Vikesaa et al., 2006). Binds to the 3'-UTR of Micropthalmia associated transcription factor mRNA and prevents the binding of miR-340 to its target sites, resulting in stabilization of the transcript, elevated expression and activity of this transcription factor (Goswami et al., 2010).

mRNA transportation: IGF2BP1 binds to the fourth and fifth exons of the oncofetal H19 RNA (Runge et al., 2000) and with ELAVL4 and G3BP to 3'-UTR of the neuron-specific TAU mRNA (Atlas et al., 2004; Atlas et al., 2007) and regulates their localization. In collaboration with IGF2BP2, IGF2BP1 binds to the conserved 54-nucleotide element in the 3'-UTR of the beta actin mRNA, known as the 'zip code'. IGF2BP1 promotes the localization of the beta-actin mRNA to dendrites (Eom et al., 2003). IGF2BP1 may act as a regulator of mRNA transport to activated synapses in response to synaptic activity.

Protein binding: IGF2BP1 interacts through the third and fourth KH domains with PABPC1 in a RNA-independent manner (Patel and Bag, 2006) and can form homo- and heterodimers with IGF2BP2 or IGF2BP3 (Nielsen et al., 2004). It interacts with fragile X metal retardation protein isoform 18 (Rackham and Brown, 2004). It interacts with DHX9, ELAVL2, HNRNPA2B1, HNRNPC, HNRNPH1, HNRNPU, IGF2BP2, IGF2BP3, ILF2 and YBX1 (Weindensdorfer et al., 2009). IGF2BP1 was identified in a mRNP granule complex, with hnRNP A1, hnRNP A2/B1, hnRNP D, hnRNP L, hnRNP Q, hnRNP R, hnRNP U, YB1/major core protein, interleukin enhancer-binding factor 2 and 3, PABP1, PABP2, PABP4, nucleolin, RNA helicase A, a series of 40 S ribosomal proteins, and the nuclear cap-binding protein CBP80 (Jønson et al., 2007). IGF2BP1 associates with HIV-1 particles. It interacts (via KH3 and KH4 domains) with HIV-1 GAG protein and diminishes viral RNA packaging, thwarts GAG processing to the cellular membranes, and impedes HIV-1 assembly (Zhou et al., 2008).

Homology The identity of human IGF2BP1 over an aligned region in UniGene is as follows:
- Pan troglodytes: 99.83%
- Canis lupas familiaris: 90.93%
- Bos taurus: 91.05%
- Mus musculus: 89.43%
- Rattus norvegicus: 89.43%

Implicated in

Entity Lung cancer
Disease IGF2BP1 is expressed in lung cancer and its expression correlates with adverse histological and clinical features and is an indicator of poor prognosis. Suppression of its expression with siRNA suppresses growth of NSCLC cells in vitro (Ioannidis et al., 2004; Kato et al., 2007).
Entity Ovarian cancer
Disease Increased expression of IGF2BP1 mRNA is associated with an advanced clinical stage and poor prognosis in patients with ovarian cancer (Köbel et al., 2007).
Entity Testicular cancer
Disease Detected in testicular carcinomas even in early stage carcinoma in situ (Hammer et al., 2005).
Entity Melanoma
Disease IGF2BP1 is highly expressed in primary human malignant melanomas and melanoma cell line (Elcheva et al., 2008).
Entity Breast cancer
Disease The IGF2BP1 gene is amplified in breast cancer (Doyle et al., 2000). Significant associations are detected between IGF2BP1 expression and the absence of estrogen receptors. IGF2BP1 collaborates with c-myc amplification to render tumours more aggressive (Ioannidis et al., 2003). Tissue specific induced expression in transgenic mice promotes tumor formation (Tessier et al., 2004).
Entity Colon cancer
Disease IGF2BP1 is scarce or absent from normal colon but is over expressed in colorectal cancer. IGF2BP1 positive tumours associate with metastasis/recurrence and shorter survival (Ross et al., 2001; Dimitriadis et al., 2007).
Entity Hepatocellular carcinoma
Disease IGF2BP1 is detected as an autoantigen in hepatocellular carcinoma (Himoto et al., 2005).
Entity Oncogenesis
Note The oncogenic action of IGF2BP1 is effected through the stabilization of the mRNA of oncogenes such as c-myc, betaTrCP1, Gli and upregulation of their expression. IGF2BP1 expression may promote metastasis by shuttling requisite RNAs to the lamellipodia of migrating cells (Vikesaa et al., 2006; Vainer et al., 2008).


Dynamic association with polysomes during P19 neuronal differentiation and an untranslated-region-dependent translation regulation of the tau mRNA by the tau mRNA-associated proteins IMP1, HuD, and G3BP1.
Atlas R, Behar L, Sapoznik S, Ginzburg I.
J Neurosci Res. 2007 Jan;85(1):173-83.
PMID 17086542
Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response.
Bennetzen MV, Larsen DH, Bunkenborg J, Bartek J, Lukas J, Andersen JS.
Mol Cell Proteomics. 2010 Jun;9(6):1314-23. Epub 2010 Feb 16.
PMID 20164059
A quantitative atlas of mitotic phosphorylation.
Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ, Gygi SP.
Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10762-7. Epub 2008 Jul 31.
PMID 18669648
Expression of oncofetal RNA-binding protein CRD-BP/IMP1 predicts clinical outcome in colon cancer.
Dimitriadis E, Trangas T, Milatos S, Foukas PG, Gioulbasanis I, Courtis N, Nielsen FC, Pandis N, Dafni U, Bardi G, Ioannidis P.
Int J Cancer. 2007 Aug 1;121(3):486-94.
PMID 17415713
The c-myc coding region determinant-binding protein: a member of a family of KH domain RNA-binding proteins.
Doyle GA, Betz NA, Leeds PF, Fleisig AJ, Prokipcak RD, Ross J.
Nucleic Acids Res. 1998 Nov 15;26(22):5036-44.
PMID 9801297
Amplification in human breast cancer of a gene encoding a c-myc mRNA-binding protein.
Doyle GA, Bourdeau-Heller JM, Coulthard S, Meisner LF, Ross J.
Cancer Res. 2000 Jun 1;60(11):2756-9.
PMID 10850408
CRD-BP protects the coding region of betaTrCP1 mRNA from miR-183-mediated degradation.
Elcheva I, Goswami S, Noubissi FK, Spiegelman VS.
Mol Cell. 2009 Jul 31;35(2):240-6.
PMID 19647520
Overexpression of mRNA-binding protein CRD-BP in malignant melanomas.
Elcheva I, Tarapore RS, Bhatia N, Spiegelman VS.
Oncogene. 2008 Aug 28;27(37):5069-74. Epub 2008 May 5.
PMID 18454174
Localization of a beta-actin messenger ribonucleoprotein complex with zipcode-binding protein modulates the density of dendritic filopodia and filopodial synapses.
Eom T, Antar LN, Singer RH, Bassell GJ.
J Neurosci. 2003 Nov 12;23(32):10433-44.
PMID 14614102
MicroRNA-340-mediated degradation of microphthalmia-associated transcription factor mRNA is inhibited by the coding region determinant-binding protein.
Goswami S, Tarapore RS, Teslaa JJ, Grinblat Y, Setaluri V, Spiegelman VS.
J Biol Chem. 2010 Jul 2;285(27):20532-40. Epub 2010 May 3.
PMID 20439467
Feedback regulation between zipcode binding protein 1 and beta-catenin mRNAs in breast cancer cells.
Gu W, Wells AL, Pan F, Singer RH.
Mol Cell Biol. 2008 Aug;28(16):4963-74. Epub 2008 May 19.
PMID 18490442
Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancer.
Hammer NA, Hansen TO, Byskov AG, Rajpert-De Meyts E, Grondahl ML, Bredkjaer HE, Wewer UM, Christiansen J, Nielsen FC.
Reproduction. 2005 Aug;130(2):203-12.
PMID 16049158
Significance of autoantibodies against insulin-like growth factor II mRNA-binding proteins in patients with hepatocellular carcinoma.
Himoto T, Kuriyama S, Zhang JY, Chan EK, Nishioka M, Tan EM.
Int J Oncol. 2005 Feb;26(2):311-7.
PMID 15645114
Spatial regulation of beta-actin translation by Src-dependent phosphorylation of ZBP1.
Huttelmaier S, Zenklusen D, Lederer M, Dictenberg J, Lorenz M, Meng X, Bassell GJ, Condeelis J, Singer RH.
Nature. 2005 Nov 24;438(7067):512-5.
PMID 16306994
CRD-BP/IMP1 expression characterizes cord blood CD34+ stem cells and affects c-myc and IGF-II expression in MCF-7 cancer cells.
Ioannidis P, Mahaira LG, Perez SA, Gritzapis AD, Sotiropoulou PA, Kavalakis GJ, Antsaklis AI, Baxevanis CN, Papamichail M.
J Biol Chem. 2005 May 20;280(20):20086-93. Epub 2005 Mar 14.
PMID 15769738
Molecular composition of IMP1 ribonucleoprotein granules.
Jonson L, Vikesaa J, Krogh A, Nielsen LK, Hansen T, Borup R, Johnsen AH, Christiansen J, Nielsen FC.
Mol Cell Proteomics. 2007 May;6(5):798-811. Epub 2007 Feb 7.
PMID 17289661
Increased expression of insulin-like growth factor-II messenger RNA-binding protein 1 is associated with tumor progression in patients with lung cancer.
Kato T, Hayama S, Yamabuki T, Ishikawa N, Miyamoto M, Ito T, Tsuchiya E, Kondo S, Nakamura Y, Daigo Y.
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):434-42.
PMID 17255263
Expression of the RNA-binding protein IMP1 correlates with poor prognosis in ovarian carcinoma.
Kobel M, Weidensdorfer D, Reinke C, Lederer M, Schmitt WD, Zeng K, Thomssen C, Hauptmann S, Huttelmaier S.
Oncogene. 2007 Nov 29;26(54):7584-9. Epub 2007 Jun 4.
PMID 17546046
Regulation of c-myc mRNA decay by translational pausing in a coding region instability determinant.
Lemm I, Ross J.
Mol Cell Biol. 2002 Jun;22(12):3959-69.
PMID 12024010
Cytoplasmic trafficking of IGF-II mRNA-binding protein by conserved KH domains.
Nielsen FC, Nielsen J, Kristensen MA, Koch G, Christiansen J.
J Cell Sci. 2002 May 15;115(Pt 10):2087-97.
PMID 11973350
Nuclear transit of human zipcode-binding protein IMP1.
Nielsen J, Adolph SK, Rajpert-De Meyts E, Lykke-Andersen J, Koch G, Christiansen J, Nielsen FC.
Biochem J. 2003 Dec 1;376(Pt 2):383-91.
PMID 12921532
A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development.
Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC.
Mol Cell Biol. 1999 Feb;19(2):1262-70.
PMID 9891060
Sequential dimerization of human zipcode-binding protein IMP1 on RNA: a cooperative mechanism providing RNP stability.
Nielsen J, Kristensen MA, Willemoes M, Nielsen FC, Christiansen J.
Nucleic Acids Res. 2004 Aug 16;32(14):4368-76. Print 2004.
PMID 15314207
Wnt signaling stimulates transcriptional outcome of the Hedgehog pathway by stabilizing GLI1 mRNA.
Noubissi FK, Goswami S, Sanek NA, Kawakami K, Minamoto T, Moser A, Grinblat Y, Spiegelman VS.
Cancer Res. 2009 Nov 15;69(22):8572-8. Epub 2009 Nov 3.
PMID 19887615
IMP1 interacts with poly(A)-binding protein (PABP) and the autoregulatory translational control element of PABP-mRNA through the KH III-IV domain.
Patel GP, Bag J.
FEBS J. 2006 Dec;273(24):5678-90.
PMID 17212783
The autoregulatory translational control element of poly(A)-binding protein mRNA forms a heteromeric ribonucleoprotein complex.
Patel GP, Ma S, Bag J.
Nucleic Acids Res. 2005 Dec 14;33(22):7074-89. Print 2005.
PMID 16356927
Visualization of RNA-protein interactions in living cells: FMRP and IMP1 interact on mRNAs.
Rackham O, Brown CM.
EMBO J. 2004 Aug 18;23(16):3346-55. Epub 2004 Jul 29.
PMID 15282548
Overexpression of an mRNA-binding protein in human colorectal cancer.
Ross J, Lemm I, Berberet B.
Oncogene. 2001 Oct 4;20(45):6544-50.
PMID 11641779
H19 RNA binds four molecules of insulin-like growth factor II mRNA-binding protein.
Runge S, Nielsen FC, Nielsen J, Lykke-Andersen J, Wewer UM, Christiansen J.
J Biol Chem. 2000 Sep 22;275(38):29562-9.
PMID 10875929
CRD-BP shields c-myc and MDR-1 RNA from endonucleolytic attack by a mammalian endoribonuclease.
Sparanese D, Lee CH.
Nucleic Acids Res. 2007;35(4):1209-21. Epub 2007 Jan 30.
PMID 17264115
ZBP1 regulates mRNA stability during cellular stress.
Stohr N, Lederer M, Reinke C, Meyer S, Hatzfeld M, Singer RH, Huttelmaier S.
J Cell Biol. 2006 Nov 20;175(4):527-34. Epub 2006 Nov 13.
PMID 17101699
Mammary tumor induction in transgenic mice expressing an RNA-binding protein.
Tessier CR, Doyle GA, Clark BA, Pitot HC, Ross J.
Cancer Res. 2004 Jan 1;64(1):209-14.
PMID 14729626
A role for VICKZ proteins in the progression of colorectal carcinomas: regulating lamellipodia formation.
Vainer G, Vainer-Mosse E, Pikarsky A, Shenoy SM, Oberman F, Yeffet A, Singer RH, Pikarsky E, Yisraeli JK.
J Pathol. 2008 Aug;215(4):445-56.
PMID 18535985
RNA-binding IMPs promote cell adhesion and invadopodia formation.
Vikesaa J, Hansen TV, Jonson L, Borup R, Wewer UM, Christiansen J, Nielsen FC.
EMBO J. 2006 Apr 5;25(7):1456-68. Epub 2006 Mar 16.
PMID 16541107
Control of c-myc mRNA stability by IGF2BP1-associated cytoplasmic RNPs.
Weidensdorfer D, Stohr N, Baude A, Lederer M, Kohn M, Schierhorn A, Buchmeier S, Wahle E, Huttelmaier S.
RNA. 2009 Jan;15(1):104-15. Epub 2008 Nov 24.
PMID 19029303
IGF2BP1 enhances HCV IRES-mediated translation initiation via the 3'UTR.
Weinlich S, Huttelmaier S, Schierhorn A, Behrens SE, Ostareck-Lederer A, Ostareck DH.
RNA. 2009 Aug;15(8):1528-42. Epub 2009 Jun 18.
PMID 19541769
The RNA-binding protein Vg1 RBP is required for cell migration during early neural development.
Yaniv K, Fainsod A, Kalcheim C, Yisraeli JK.
Development. 2003 Dec;130(23):5649-61. Epub 2003 Oct 1.
PMID 14522877
Insulin-like growth factor II mRNA binding protein 1 associates with Gag protein of human immunodeficiency virus type 1, and its overexpression affects virus assembly.
Zhou Y, Rong L, Lu J, Pan Q, Liang C.
J Virol. 2008 Jun;82(12):5683-92. Epub 2008 Apr 2.
PMID 18385235


This paper should be referenced as such :
Trangas, T ; Ioannidis, P
IGF2BP1 (insulin-like growth factor 2 mRNA binding protein 1)
Atlas Genet Cytogenet Oncol Haematol. 2011;15(7):562-566.
Free journal version : [ pdf ]   [ DOI ]

Other Leukemias implicated (Data extracted from papers in the Atlas) [ 1 ]
  t(14;17)(q32;q21) IGH::IGF2BP1

External links


HGNC (Hugo)IGF2BP1   28866
Entrez_Gene (NCBI)IGF2BP1    insulin like growth factor 2 mRNA binding protein 1
AliasesCRD-BP; CRDBP; IMP-1; IMP1; 
GeneCards (Weizmann)IGF2BP1
Ensembl hg19 (Hinxton)ENSG00000159217 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000159217 [Gene_View]  ENSG00000159217 [Sequence]  chr17:48997385-49056145 [Contig_View]  IGF2BP1 [Vega]
ICGC DataPortalENSG00000159217
TCGA cBioPortalIGF2BP1
Genatlas (Paris)IGF2BP1
SOURCE (Princeton)IGF2BP1
Genetics Home Reference (NIH)IGF2BP1
Genomic and cartography
GoldenPath hg38 (UCSC)IGF2BP1  -     chr17:48997385-49056145 +  17q21.32   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)IGF2BP1  -     17q21.32   [Description]    (hg19-Feb_2009)
GoldenPathIGF2BP1 - 17q21.32 [CytoView hg19]  IGF2BP1 - 17q21.32 [CytoView hg38]
Genome Data Viewer NCBIIGF2BP1 [Mapview hg19]  
Gene and transcription
Genbank (Entrez)AF117106 AF198254 AK022617 AK022784 AK074915
RefSeq transcript (Entrez)NM_001160423 NM_006546
Consensus coding sequences : CCDS (NCBI)IGF2BP1
Gene ExpressionIGF2BP1 [ NCBI-GEO ]   IGF2BP1 [ EBI - ARRAY_EXPRESS ]   IGF2BP1 [ SEEK ]   IGF2BP1 [ MEM ]
Gene Expression Viewer (FireBrowse)IGF2BP1 [ Firebrowse - Broad ]
GenevisibleExpression of IGF2BP1 in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)10642
GTEX Portal (Tissue expression)IGF2BP1
Human Protein AtlasENSG00000159217-IGF2BP1 [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtQ9NZI8   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtQ9NZI8  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProQ9NZI8
Domaine pattern : Prosite (Expaxy)KH_TYPE_1 (PS50084)    RRM (PS50102)   
Domains : Interpro (EBI)IGF2BP1_RRM1    IGF2BP1_RRM2    KH_dom    KH_dom_type_1    KH_dom_type_1_sf    Nucleotide-bd_a/b_plait_sf    RBD_domain_sf    RRM_dom   
Domain families : Pfam (Sanger)KH_1 (PF00013)    RRM_1 (PF00076)   
Domain families : Pfam (NCBI)pfam00013    pfam00076   
Domain families : Smart (EMBL)KH (SM00322)  RRM (SM00360)  
Conserved Domain (NCBI)IGF2BP1
PDB Europe3KRM    6QEY   
PDB (PDBSum)3KRM    6QEY   
PDB (IMB)3KRM    6QEY   
Structural Biology KnowledgeBase3KRM    6QEY   
SCOP (Structural Classification of Proteins)3KRM    6QEY   
CATH (Classification of proteins structures)3KRM    6QEY   
AlphaFold pdb e-kbQ9NZI8   
Human Protein Atlas [tissue]ENSG00000159217-IGF2BP1 [tissue]
Protein Interaction databases
IntAct (EBI)Q9NZI8
Complex Portal (EBI)Q9NZI8 CPX-1080 CRD-mediated mRNA stability complex
Ontologies - Pathways
Ontology : AmiGOregulation of cytokine production  RNA binding  mRNA binding  mRNA binding  mRNA 3'-UTR binding  mRNA 3'-UTR binding  protein binding  nucleus  nucleoplasm  cytoplasm  cytoplasm  cytosol  cytosol  cytosol  nervous system development  regulation of gene expression  cytoplasmic stress granule  regulation of mRNA stability involved in response to stress  negative regulation of translation  pallium cell proliferation in forebrain  lamellipodium  filopodium  growth cone  neuronal cell body  dendritic spine  regulation of mRNA stability  translation regulator activity  mRNA 5'-UTR binding  perinuclear region of cytoplasm  mRNA transport  regulation of RNA metabolic process  CRD-mediated mRNA stabilization  CRD-mediated mRNA stability complex  neuronal stem cell population maintenance  dendrite arborization  ribonucleoprotein complex  
Ontology : EGO-EBIregulation of cytokine production  RNA binding  mRNA binding  mRNA binding  mRNA 3'-UTR binding  mRNA 3'-UTR binding  protein binding  nucleus  nucleoplasm  cytoplasm  cytoplasm  cytosol  cytosol  cytosol  nervous system development  regulation of gene expression  cytoplasmic stress granule  regulation of mRNA stability involved in response to stress  negative regulation of translation  pallium cell proliferation in forebrain  lamellipodium  filopodium  growth cone  neuronal cell body  dendritic spine  regulation of mRNA stability  translation regulator activity  mRNA 5'-UTR binding  perinuclear region of cytoplasm  mRNA transport  regulation of RNA metabolic process  CRD-mediated mRNA stabilization  CRD-mediated mRNA stability complex  neuronal stem cell population maintenance  dendrite arborization  ribonucleoprotein complex  
Pathways : KEGGMicroRNAs in cancer   
REACTOMEQ9NZI8 [protein]
REACTOME PathwaysR-HSA-5687128 [pathway]   
NDEx NetworkIGF2BP1
Atlas of Cancer Signalling NetworkIGF2BP1
Wikipedia pathwaysIGF2BP1
Orthology - Evolution
GeneTree (enSembl)ENSG00000159217
Phylogenetic Trees/Animal Genes : TreeFamIGF2BP1
Homologs : HomoloGeneIGF2BP1
Homology/Alignments : Family Browser (UCSC)IGF2BP1
Gene fusions - Rearrangements
Fusion : MitelmanIGH::IGF2BP1 [14q32.33/17q21.32]  
Fusion : MitelmanKAT7::IGF2BP1 [17q21.33/17q21.32]  
Fusion : MitelmanPRKCA::IGF2BP1 [17q24.2/17q21.32]  
Fusion : MitelmanRAI1::IGF2BP1 [17p11.2/17q21.32]  
Fusion : MitelmanZBTB8OS::IGF2BP1 [1p35.1/17q21.32]  
Fusion : QuiverIGF2BP1
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerIGF2BP1 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)IGF2BP1
Exome Variant ServerIGF2BP1
GNOMAD BrowserENSG00000159217
Varsome BrowserIGF2BP1
ACMGIGF2BP1 variants
Genomic Variants (DGV)IGF2BP1 [DGVbeta]
DECIPHERIGF2BP1 [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisIGF2BP1 
ICGC Data PortalIGF2BP1 
TCGA Data PortalIGF2BP1 
Broad Tumor PortalIGF2BP1
OASIS PortalIGF2BP1 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICIGF2BP1  [overview]  [genome browser]  [tissue]  [distribution]  
Somatic Mutations in Cancer : COSMIC3DIGF2BP1
Mutations and Diseases : HGMDIGF2BP1
LOVD (Leiden Open Variation Database)[gene] [transcripts] [variants]
DgiDB (Drug Gene Interaction Database)IGF2BP1
DoCM (Curated mutations)IGF2BP1
CIViC (Clinical Interpretations of Variants in Cancer)IGF2BP1
NCG (London)IGF2BP1
Impact of mutations[PolyPhen2] [Provean] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Genetic Testing Registry IGF2BP1
NextProtQ9NZI8 [Medical]
Target ValidationIGF2BP1
Huge Navigator IGF2BP1 [HugePedia]
Clinical trials, drugs, therapy
Protein Interactions : CTDIGF2BP1
Pharm GKB GenePA143485501
Clinical trialIGF2BP1
DataMed IndexIGF2BP1
PubMed244 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Oct 8 21:20:05 CEST 2021

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us